Patents Assigned to Genomed
-
Patent number: 6998404Abstract: Adenosine receptor antagonists, especially aminophyllline, are used to treat or prevent acute renal failure. In the preferred embodiment, aminophylline is administered by infusion so that it does not exceed a serum theophylline level of 15-20 micrograms/ml, most preferably the aminophylline is administered to achieve a serum theophylline concentration of 3-10 micrograms/ml, with an infusion rate of 0.1-0.6 mg/kg IBW/hour (IBW=ideal body weight). The adenosine receptor antagonist can also be used to help sustain a kidney for transplant purposes. Preferably, aminophylline is loaded while the kidney is still part of the donor. A dose of aminophylline of 5 mg/kg lean body weight is infused into the donor over a 30-60 min period, with cardiac monitoring. The infusion dose is decreased in the event of supraventricular or ventricular tachycardias. The kidney is removed and placed in the standard “cold” bath, but containing aminophylline at a dose of 5-10 micrograms/ml (5-10 mg/l).Type: GrantFiled: August 8, 2002Date of Patent: February 14, 2006Assignee: GenoMed, LLCInventor: David W. Moskowitz
-
Patent number: 6939534Abstract: A method of treating pulmonary hypoplasia in infants has been developed, wherein epidermal growth factor (EGF) is administered to the pulmonary system of an infant in need of treatment thereof. The EGF is administered as an aerosol or dry powder directly to the pulmonary tree, or into the amniotic fluid before birth if a situation such as oligohydramnios is recognized pre-term. The method can also be used to treat persistent pulmonary hypertension of the newborn. A hydrophobic angiotensin I-converting enzyme (ACE) inhibitor such as ramipril can also be used for the oral treatment of persistent pulmonary hypertension of the newborn.Type: GrantFiled: August 8, 2002Date of Patent: September 6, 2005Assignee: GenoMed, LLCInventor: David W. Moskowitz
-
Publication number: 20030040509Abstract: Over 40 common diseases, in addition to congestive heart failure (CHF) due to hypertension (HTN) or non-insulin dependent diabetes mellitus (type II diabetes mellitus) (NIDDM), atherosclerotic peripheral vascular disease (ASPVD) due to HTN or NIDDM, and chronic obstructive pulmonary disease; emphysema (COPD), are associated with the ACE D/D genotype and should also respond to an adequate tissue-inhibitory dose of ACE inhibitors such as quinapril. Several of these diseases have now been successfully treated using higher than normal dosages of ACE inhibitors, especially hydrophobic ACE inhibitors, with good outcomes. ACE inhibitors have also been found to be useful in inhibiting apoptosis and aging in general. Dosages that have been utilized are typically greater than quinapril at a dose of 40 to 80 mg/day, i.e. up to 1 mg/kg per day for a “typical” 80 kg patient.Type: ApplicationFiled: August 6, 2002Publication date: February 27, 2003Applicant: GenoMed, LLCInventor: David W. Moskowitz
-
Publication number: 20030032598Abstract: A method of treating pulmonary hypoplasia in infants has been developed, wherein epidermal growth factor (EGF) is administered to the pulmonary system of an infant in need of treatment thereof. The EGF is administered as an aerosol or dry powder directly to the pulmonary tree, or into the amniotic fluid before birth if a situation such as oligohydramnios is recognized pre-term. The method can also be used to treat persistent pulmonary hypertension of the newborn. A hydrophobic angiotensin I-converting enzyme (ACE) inhibitor such as ramipril can also be used for the oral treatment of persistent pulmonary hypertension of the newborn.Type: ApplicationFiled: August 8, 2002Publication date: February 13, 2003Applicant: GenoMed, LLCInventor: David W. Moskowitz
-
Publication number: 20030032650Abstract: Adenosine receptor antagonists, especially aminophyllline, are used to treat or prevent acute renal failure. In the preferred embodiment, aminophylline is administered by infusion so that it does not exceed a serum theophylline level of 15-20 micrograms/ml, most preferably the aminophylline is administered to achieve a serum theophylline concentration of 3-10 micrograms/ml, with an infusion rate of 0.1-0.6 mg/kg IBW/hour (IBW=ideal body weight). The adenosine receptor antagonist can also be used to help sustain a kidney for transplant purposes. Preferably, aminophylline is loaded while the kidney is still part of the donor. A dose of aminophylline of 5 mg/kg lean body weight is infused into the donor over a 30-60 min period, with cardiac monitoring. The infusion dose is decreased in the event of supraventricular or ventricular tachycardias. The kidney is removed and placed in the standard “cold” bath, but containing aminophylline at a dose of 5-10 micrograms/ml (5-10 mg/l).Type: ApplicationFiled: August 8, 2002Publication date: February 13, 2003Applicant: GenoMed, LLC DEInventor: David W. Moskowitz
-
Publication number: 20020197632Abstract: A way of identifying disease associated genes, and their mis-regulation, has been developed.Type: ApplicationFiled: May 2, 2002Publication date: December 26, 2002Applicant: GenoMed, LLCInventor: David W. Moskowitz
-
Patent number: 5843312Abstract: A chromatography material is described for separation of nucleic acid mixtures in which a support is converted with a silanization reagent, in which the silanization reagent has a reactive group converted with silanization reagent, in which the silanization reagent has a reactive group converted with an alkyl- or dialkylamine, or contains a reactive group that can be converted with an alkyl- or dialkylamine, which is then reacted with the alkyl- or dialkylamine.Type: GrantFiled: October 23, 1996Date of Patent: December 1, 1998Assignee: GenomedInventors: Thomas Manz, Jochen Tittgen